Biotech Values

[iwfal]

why didn’t AGIX position this as primarily a diabetes drug?

They kinda did - the primary enrollment criteria for ARISE was diabetes. Other possible criteria were fallbacks.

But my guess is that, like a lot of biotechs, they jumped too quickly to ph iii. This, in combo with the fact that the parent drug is primarily a heart drug, resulted in a cardio trial.